Resistance to amphotericin B: emerging clinical and microbiological patterns

Timothy R. Sterling, William G. Merz

Research output: Contribution to journalReview articlepeer-review

Abstract

There has been an increasing number of reports of clinically significant amphotericin B (AmB) resistance in fungal pathogens, including Candida albicans. Concommitantly, advances in antifungal susceptibility testing have led to an improved correlation between microbiologic and clinical failure. Reports of AmB resistance, correlation of results and in vitro/in vivo correlations, mechanisms of resistance, and the transmission of resistant isolates within confined environments are reviewed. Recommendations are given regarding the clinical settings in which AmB susceptibility testing should be considered.

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalDrug Resistance Updates
Volume1
Issue number3
DOIs
StatePublished - Dec 1 1998

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Resistance to amphotericin B: emerging clinical and microbiological patterns'. Together they form a unique fingerprint.

Cite this